A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Part of paid clinical trials in Duarte, California.
- Sponsor
- Pierre Fabre Medicament
- Study ID
- NCT03394365
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Allogeneic Hematopoietic Cell Transplant
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Lymphoproliferative Disorders
- Solid Organ Transplant Complications
- Stem Cell Transplant Complications
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- tabelecleucel — BIOLOGICALTabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
Study Details
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Key Dates
- Start date
- Dec 29, 2017
- Status verified
- May 2026
- Primary completion
- May 31, 2030
- Completion
- Aug 31, 2030
Study Design
- Enrollment
- 115 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort SOT-R (C-SOT-R)Participants with EBV+ PTLD following SOT that has failed rituximab will receive IV tabelecleucel.
- Experimental: Cohort SOT-R+C (C-SOT-R+C)Participants with EBV+ PTLD following SOT that has failed both rituximab and chemotherapy will receive IV tabelecleucel.
- Experimental: Cohort HCT (C-HCT)Participants with EBV+ PTLD following HCT that has failed rituximab containing regimen will receive IV tabelecleucel.
Primary Outcome Measure
Objective Response Rate (ORR) in the Analysis Cohorts C-SOT, C-HCT, and Combined Population (C-SOT-R+C, C-SOT-R-Ci, and C-HCT) Who Received Commercial Product, or a Product Manufactured Using a Comparable PV [ Time Frame: 2 years ]
Central Contacts
- Anke Friedetzky(000) 000-0000
- Marie Bosredon7 84 14 59 82
Locations (40)
Find similar trials in Duarte, CA
By research site
City of Hope (Adults and Pediatrics)· Duarte, CAUniversity of California San Diego Moores Cancer Center (Adults only)· La Jolla, CALoma Linda University Medical Center (Adults only)· Loma Linda, CAChildren's Hospital Los Angeles, Div. of Research Immunology/BMT (Adults and Pediatrics)· Los Angeles, CAUCLA Medical Center (Adults and Pediatrics)· Los Angeles, CAUniversity of California Davis Comprehensive Cancer Center (Adults only)· Sacramento, CA
Related Studies
- Establishing a Tumor Bank in Families With Multiple Lymphoproliferative MalignanciesRecruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- Pathogenesis of Hematologic MalignanciesEnrolling By Invitation · OHSU Knight Cancer Institute · Portland, Oregon
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary ImmunodeficienciesPHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell LymphomaPHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland